A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Retinoschisin (rAAV2tYF-CB-hRS1) in Patients With X-linked Retinoschisis

Trial Profile

A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Retinoschisin (rAAV2tYF-CB-hRS1) in Patients With X-linked Retinoschisis

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs AAV RS1 (Primary)
  • Indications Retinoschisis
  • Focus Adverse reactions
  • Sponsors Applied Genetic Technologies Corporation
  • Most Recent Events

    • 10 Apr 2018 According to the Applied Genetic Technologies Corporation media release, topline data from this study is expected in Q4 2018 with the final analysis at the twelve-month time point.
    • 10 Apr 2018 Status changed from recruiting to active, no longer recruiting, according to the Applied Genetic Technologies Corporation media release.
    • 09 Feb 2018 According to an AGTC media release, the company expects to present data after the last patient enrolled has been followed for six months.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top